Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Beth Woods; Mark Sculpher; Robert Hughes; John M. Russell; Melissa Gannon; Mahesh Parmar; Angus Robinson; John Wagstaff; Narayanan Srihari; Nicholas D. James; David P. Dearnaley; John Staffurth; George N. Thalmann; Malcolm D. Mason; William Cross; Audrey Cook; Shaun Tolan; Robert J. Jones; Joe M. O’Sullivan; Richard Cathomas; C. Peedell; Matthew R. Sydes; Matthew Simms; Joanna Gale; Omi Parikh; David Matheson; Mymoona Alzouebi; Alison Birtle; Santhanam Sundar; Susannah Brock; John D. Graham; Andrew Protheroe; Anna Tran; E.G. Sideris; Christopher Parker; Rajaguru Srinivasan; David Tsang; A.W.S. Ritchie; Robert Laing; Prabir Chakraborti; Stephanie Gibbs; Gerhardt Attard; Robin Millman; Duncan B. McLaren

doi:10.1016/j.euo.2018.06.004

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Beth Woods(University of York), Mark Sculpher(University of York), Robert Hughes(Mount Vernon Hospital), John M. Russell, Melissa Gannon(MRC Clinical Trials Unit at UCL), Mahesh Parmar(University College London), Angus Robinson(Royal Sussex County Hospital), John Wagstaff(Maastricht University Medical Centre), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), Nicholas D. James(Royal Marsden NHS Foundation Trust), David P. Dearnaley(Royal Marsden NHS Foundation Trust), John Staffurth(Velindre NHS Trust), George N. Thalmann(University Hospital of Bern), Malcolm D. Mason(Royal Marsden Hospital), William Cross(Leeds Teaching Hospitals NHS Trust), Audrey Cook(University College London), Shaun Tolan(Clatterbridge Cancer Centre NHS Foundation Trust), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), Richard Cathomas(Kantonsspital Graubünden), C. Peedell(South Tees Hospitals NHS Foundation Trust), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Matthew Simms(Hull and East Yorkshire Hospitals NHS Trust), Joanna Gale(Queen Alexandra Hospital), Omi Parikh(Royal Blackburn Teaching Hospital), David Matheson(MRC Clinical Trials Unit at UCL), Mymoona Alzouebi(Weston Park Cancer Centre), Alison Birtle(University of Lancashire), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Susannah Brock, John D. Graham(Charles Sturt University), Andrew Protheroe(Churchill Hospital), Anna Tran(Centre Hospitalier Universitaire de Sherbrooke), E.G. Sideris(University of York), Christopher Parker(Royal Marsden NHS Foundation Trust), Rajaguru Srinivasan(Royal Devon and Exeter Hospital), David Tsang(Basildon Hospital), A.W.S. Ritchie(MRC Clinical Trials Unit at UCL), Robert Laing(Royal Surrey County Hospital), Prabir Chakraborti(Royal Derby Hospital), Stephanie Gibbs(Queen's Hospital), Gerhardt Attard(London Cancer), Robin Millman(MRC Clinical Trials Unit at UCL), Duncan B. McLaren(NHS Lothian)

European Urology Oncology

September 14, 2018

10.1016/j.euo.2018.06.004

Cited by 27

Related Papers

Integrative Clinical Genomics of Advanced Prostate Cancer

|Cell|2015|3.6k

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

|New England Journal of Medicine|2013|3.3k

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

|New England Journal of Medicine|2015|2.2k

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

|European Urology|2020|2.2k

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k